NANOSTRUCTURED LIPID CARRIERS FOR DRUG DELIVERY: FORMULATION DESIGN, CHARACTERIZATION, TRANSLATIONAL CHALLENGES, AND EMERGING STRATEGIES – A CRITICAL REVIEW

Nanostructured lipid carriers (NLCs) are lipid-based nanoparticles created from a blend of solid and liquid lipids, with surfactants that help stabilize the mixture. The introduction of liquid lipid can disrupt the orderly arrangement of solid lipid, resulting in spaces that can hold a drug. This structure may enhance drug loading or minimize drug loss during storage, particularly in comparison to certain solid lipid nanoparticle (SLN) systems. The benefits of this approach depend on factors such as the type of drug, the lipid mixture, the surfactant system, and the methods used in manufacturing. This review explores the foundational aspects of NLC formulation, the selection of materials, preparation techniques, and the analytical assessments used to characterize these systems. It also looks at their reported applications across various administration routes, including oral, dermal, transdermal, ocular, pulmonary, nasal, and brain-targeted delivery. The review places significant emphasis on the challenges of transforming a laboratory formulation into a reliable pharmaceutical product, such as variability between batches, inadequate understanding of particle structure, issues with physical and chemical stability, sterilization, scaling up, route-specific safety, and regulatory requirements. Potential solutions to these challenges include Quality-by-Design (QbD), Design of Experiments (DoE), advanced analytical techniques, continuous processing, lyophilization, and surface modification. It is important to note that NLCs should not be seen as universally superior carriers; their effectiveness must be established for each drug and intended delivery route, ideally in comparison to an appropriate reference and using clinically significant outcomes.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-18
DOI
https://doi.org/10.5281/zenodo.24331737
Primary Topic
Advancements in Transdermal Drug Delivery
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

NANOSTRUCTURED LIPID CARRIERS FOR DRUG DELIVERY: FORMULATION DESIGN, CHARACTERIZATION, TRANSLATIONAL CHALLENGES, AND EMERGING STRATEGIES – A CRITICAL REVIEW

Aastha Gupta, Kalpana Verma
2 links
Zenodo (CERN European Organization for Nuclear Research)
Advancements in Transdermal Drug Delivery
article

NANOSTRUCTURED LIPID CARRIERS FOR DRUG DELIVERY: FORMULATION DESIGN, CHARACTERIZATION, TRANSLATIONAL CHALLENGES, AND EMERGING STRATEGIES – A CRITICAL REVIEW

Aastha Gupta, Kalpana Verma
article en

Abstract

Nanostructured lipid carriers (NLCs) are lipid-based nanoparticles created from a blend of solid and liquid lipids, with surfactants that help stabilize the mixture. The introduction of liquid lipid can disrupt the orderly arrangement of solid lipid, resulting in spaces that can hold a drug. This structure may enhance drug loading or minimize drug loss during storage, particularly in comparison to certain solid lipid nanoparticle (SLN) systems. The benefits of this approach depend on factors such as the type of drug, the lipid mixture, the surfactant system, and the methods used in manufacturing. This review explores the foundational aspects of NLC formulation, the selection of materials, preparation techniques, and the analytical assessments used to characterize these systems. It also looks at their reported applications across various administration routes, including oral, dermal, transdermal, ocular, pulmonary, nasal, and brain-targeted delivery. The review places significant emphasis on the challenges of transforming a laboratory formulation into a reliable pharmaceutical product, such as variability between batches, inadequate understanding of particle structure, issues with physical and chemical stability, sterilization, scaling up, route-specific safety, and regulatory requirements. Potential solutions to these challenges include Quality-by-Design (QbD), Design of Experiments (DoE), advanced analytical techniques, continuous processing, lyophilization, and surface modification. It is important to note that NLCs should not be seen as universally superior carriers; their effectiveness must be established for each drug and intended delivery route, ideally in comparison to an appropriate reference and using clinically significant outcomes.

Zenodo (CERN European Organization for Nuclear Research)
Good health and well-being
Advancements in Transdermal Drug Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon